Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
NY-ESO-1 Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
The CTA (Cancer-testis antigens) New York Esophageal Squamous Cell Carcinoma-1 (NY-ES0-1), also known as CTAG1B, is a protein which is encoded by the gene CTGAG1B, and located on the Xq28 region of the X chromosome. NY-ESO-1 is an archetypical example of a CTA with restricted expression to germ cells and placenta cells and re-expression in tumor cells. NY-ESO-1 expression has been reported in a wide range of tumor types, including neuroblastoma, myeloma, metastatic melanoma, synovial sarcoma, bladder cancer, non-small cell lung cancer, esophageal cancer, hepatocellular cancer, head and neck cancer, ovarian cancer, prostate cancer and breast cancer. Additionally, within these tumor types, the expression frequency of NY-ESO-1 differs greatly with the most commonly expressing tumors being myxoid and round liposarcoma (89-100%), neuroblastoma (82%), synovial sarcoma (80%), melanoma (46%), and ovarian cancer (43%), and others (20-40%). Hence, ongoing clinical trials targeting NY-ESO-1, by using a vaccination approach, adoptive cellular therapy, or combination treatment with immune checkpoint inhibitors are being conducted by companies. Merck (MSD), Takara Bio., BioNTech, Marker Therapeutics, GSK, Lyell Immunopharma, Gilead Science, and Axis Therapeutics are some of the pharmaceutical companies with NY-ESO-1 inhibitor in their pipeline.
Key Market Developments:
Drugs under the Pipeline for NY-ESO-1 Inhibitors:
Clinical Activity and Developments of NY-ESO-1 Inhibitors:
Currently, there are about 23 drug molecules in ongoing clinical trials, which are being developed by 23 companies for NY-ESO-1 inhibitor.
Molecules Name |
Number of Studies |
Rasdegafusp alfa (CDX-1401) |
10 |
Letetresgene autoleucel (GSK3377794) |
9 |
NY-ESO-1 TCR |
8 |
TAEST16001 |
5 |
CMB305 |
4 |
MultiTAA T cell therapy |
4 |
ID-LV305 |
3 |
Mipetresgene autoleucel (TBI-1301) |
3 |
BNT111 |
2 |
MT-601 |
2 |
ADXS-503 |
1 |
GSK2241658A |
1 |
GSK3845097 |
1 |
GSK3901961 |
1 |
HBI 0201-ESO TCRT |
1 |
IDC-G305 |
1 |
IMM65 |
1 |
LYL132 |
1 |
NY-ESO-1 TCR-T cell therapy |
1 |
PDC*lung01 |
1 |
TC-N201 |
1 |
TCRT-ESO-A2 |
1 |
VTP-600 |
1 |
The drug molecules in clinical trials such as Rasdegafusp alfa (CDX-1401) by Celldex is in phase-I/II for platinum-resistant fallopian tube carcinoma, ovarian cancer, and primary peritoneal carcinoma. Takara Bio’s Mipetresgene autoleucel (TB-1301) is in phase-I/II for synovial sarcoma and in phase-I for NY-ESO-1 expressing solid tumors in HLA-A2 positive patients, esophageal cancer, ovarian cancer, lung cancer, bladder, and liver cancer. Merck (MSD)’s LV305 is in phase-I for HLA-A 0201 positive cells, recurrent myxoid liposarcoma, and recurrent synovial sarcoma. BioNTech’s BNT111 is in phase-II for melanoma stage III, melanoma stage IV, and unresectable melanoma. Marker Therapeutics’ MT401 are in phase-II for breast cancer, in phase-I for leukaemia, non-Hodgkin lymphoma, and acute myeloid leukaemia and MT601 is in phase-I/II for pancreatic cancer.
Download Free Sample Report
Rasdegafusp alfa (CDX-1401), Letetresgene autoleucel (GSK3377794), MultiTAA T cell thera, ID-LV30, Mipetresgene autoleucel (TBI-1301), BNT111, MT-601, and LYL132 are few of the drugs in the pipeline for NY-ESO-1 inhibitors.
Merck (MSD), Takara Bio. BioNTech, Marker Therapeutics, GSK, Lyell Immunopharma, Gilead Science, and Axis Therapeutics are some of the pharmaceutical companies with NY-ESO-1 inhibitor in their pipeline.
Major Indications for NY-ESO-1 inhibitors are myeloma, metastatic melanoma, synovial sarcoma, bladder cancer, non-small cell lung cancer, esophageal cancer, hepatocellular cancer, head and neck cancer, ovarian cancer, prostate cancer, breast cancer, and others.
There are a total of 23 molecules are in the Phase-I/II clinical development for NY-ESO-1 inhibitors.
Key Market Players